<DOC>
	<DOCNO>NCT00120770</DOCNO>
	<brief_summary>This Phase 3 , multi-center , randomize , placebo-controlled trial determine effectiveness safety 6 % cellulose sulfate ( CS ) vaginal gel prevention HIV infection .</brief_summary>
	<brief_title>Cellulose Sulfate ( CS ) Gel HIV Nigeria</brief_title>
	<detailed_description>This Phase 3 , multi-center , randomize , placebo-controlled trial ass effectiveness CS gel prevent male-to-female vaginal transmission HIV among HIV sero-negative woman high risk HIV infection . Eligible participant HIV negative , risk become infect , willing use vaginal microbicide time intercourse throughout 12 month study participation recruit Port Harcourt Lagos , Nigeria . The enrollment phase last 2,160 woman enrol . It anticipate enrollment complete within 12 month .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Chlamydia Infections</mesh_term>
	<mesh_term>Gonorrhea</mesh_term>
	<mesh_term>Anti-Infective Agents</mesh_term>
	<criteria>Willing able give inform consent At least 18 year old 35 year old Average three vaginal coital act per week male partner More one male sexual partner last 3 month Willing use study product direct Willing adhere followup schedule Willing participate study 12 month Willing report selfmedication study participation Willing give urine pregnancy test ; selfadministered vaginal swab GC/CT test ; OMT HIV monthly ; finger prick HIV confirmation require ; blood draw syphilis HIV baseline , HIV final visit Willing use spermicide , vaginal contraceptive , vaginal lubricant study At least 3 month since end last pregnancy History adverse reaction study product , include latex Pregnant desire pregnancy 12 month participation Injection drug user Gynecological abnormality may impact safety and/or response study gel accord investigator HIV positive diagnose OraQuick® rapid test Participation microbicide research Discontinued CS study previously Any condition ( social medical ) , opinion investigator , would make study participation unsafe complicate data interpretation</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>February 2007</verification_date>
	<keyword>AE adverse event</keyword>
	<keyword>AIDS acquire immunodeficiency syndrome</keyword>
	<keyword>ALT ( SGPT ) alanine aminotransferase</keyword>
	<keyword>ART antiretroviral therapy</keyword>
	<keyword>AST ( SGOT ) aspartate aminotransferase</keyword>
	<keyword>DCF data collection form</keyword>
	<keyword>DMC Data Monitoring Committee</keyword>
	<keyword>FDA ( U.S. ) Food Drug Administration</keyword>
	<keyword>GCP Good Clinical Practice guideline</keyword>
	<keyword>HB sAg Hepatitis B surface antigen</keyword>
	<keyword>ICH International Conference Harmonisation</keyword>
	<keyword>IND Investigational New Drug Application</keyword>
	<keyword>IRB Institutional Review Board</keyword>
	<keyword>IU international unit</keyword>
	<keyword>mg milligram ( )</keyword>
	<keyword>mm3 cubic millimeter ( )</keyword>
	<keyword>PCR polymerase chain reaction</keyword>
	<keyword>SAE serious adverse event</keyword>
	<keyword>µg microgram</keyword>
	<keyword>ULN upper limit normal range</keyword>
	<keyword>WB Western Blot</keyword>
	<keyword>Human Immunodeficiency Virus</keyword>
	<keyword>Neisseria gonorrhoeae</keyword>
	<keyword>Chlamydia trachomatis</keyword>
	<keyword>HIV Seronegativity</keyword>
</DOC>